Naim Zaki, MD

Long-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression: final results of the SUSTAIN-3 study

In a long-term study (up to 6.6 years) of intermittently-dosed esketamine with daily antidepressant, early improvement in depression was maintained and no new safety signal was identified...

Naim Zaki , MD;

10/26/2023

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

March 27 ⁠–⁠ March 30

See Full Calendar

Naim Zaki, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products